EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Macrophage Migration Inhibitory Factor and Interleukin 1-β mRNA Levels as Predictors of Antidepressant Treatment Response in Major Depression

Henry R Kranzler, Annjanette Stone, Steven A Schichman, L Michelle Griffin, Hannah Roggenkamp, Michael E Thase, Kevin G Lynch, David W Oslin

Psychopharmacology Bulletin · 2025

DOI: 10.64719/pb.4509 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Psychopharmacology Bulletin, 2025. Verfasst von Henry R Kranzler und 7 weiteren Autor:innen. Beteiligte Einrichtung: Kranzler, MD, Veterans Integrated Service Network 4, Mental Illness Research, Education and Clinical Center, Crescenz Veterans Affairs Medical Center…. Hauptthemen laut MEDLINE: Macrophage Migration-Inhibitory Factors, Antidepressive Agents, Major Depressive Disorder, Interleukin-1beta. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunologic measures have been studied as predictors of who will respond to standard antidepressants. Two previous, small studies of pretreatment leukocyte mRNA expression levels of the cytokines macrophage migration inhibitory factor (MIF) and interleukin 1-beta (IL1-β) identified antidepressant treatment responders.

Methods

We tested these findings in 1,299 patients from the PRIME Care study, a multi-center pharmacogenetic depression treatment trial. Patients underwent 5 depression-symptom assessments over 24 weeks. mRNA was extracted from peripheral blood, purified, and assayed with TaqMan gene expression assays and a known copy number calibrator to yield relative quantification and copy numbers for each sample. In generalized estimating equations models, we regressed the repeated depression measures and a binary treatment response measure on the baseline MIF and IL-1β measures and relevant covariates.

Results

Participants’ depression scores decreased monotonically during treatment, with the treatment response percentage increasing concomitantly. We found no significant associations of the cytokine concentrations with either the change in depression scores or the likelihood of a treatment response. A secondary analysis limited to a subsample of 126 participants selected to remove the potential for confounding also showed no significant associations.

Limitations

Despite efforts to control for sample and assay method differences, these could have contributed to the lack of replication of prior research.

Conclusions

We did not replicate prior findings that pre-treatment expression levels for two cytokines predicted antidepressant treatment response. This raises questions about the clinical utility of using these biomarkers in treating depression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Macrophage Migration-Inhibitory FactorsAntidepressive AgentsMajor Depressive DisorderInterleukin-1betaRNA, MessengerIntramolecular OxidoreductasesHumansMaleFemaleMiddle AgedAdultTreatment OutcomeAged

Stichwörter der Autor:innen

antidepressant treatmentcytokinesmajor depressive disorderpredicting treatment outcome

Substanzen

Macrophage Migration-Inhibitory FactorsAntidepressive AgentsInterleukin-1betaRNA, MessengerMIF protein, humanIntramolecular OxidoreductasesIL1B protein, human

Autor:innen und Institutionen

  • Kranzler, MD, Veterans Integrated Service Network 4, Mental Illness Research, Education and Clinical Center, Crescenz Veterans Affairs Medical Center and Department of Psychiatry, University of Pennsylvania Perelman Sch…
  • Stone, Pharmacogenomics Analysis Laboratory, Central Arkansas Veterans Healthcare System, Little Rock, AR.
  • Schichman, MD, PhD, Pharmacogenomics Analysis Laboratory, Central Arkansas Veterans Healthcare System, Little Rock, AR.
  • Griffin, Pharmacogenomics Analysis Laboratory, Central Arkansas Veterans Healthcare System, Little Rock, AR.
  • Roggenkamp, MD, VA Connecticut Healthcare System Department of Psychiatry, Yale School of Medicine, New Haven, CT.
  • Thase, MD, Veterans Integrated Service Network 4, Mental Illness Research, Education and Clinical Center, Crescenz Veterans Affairs Medical Center and Department of Psychiatry, University of Pennsylvania Perelman School…

Förderung

  • NCATS NIH HHS

Zitieren

APA

Kranzler, H. R., Stone, A., Schichman, S. A., Griffin, L. M., Roggenkamp, H., Thase, M. E., Lynch, K. G., & Oslin, D. W. (2025). Macrophage Migration Inhibitory Factor and Interleukin 1-β mRNA Levels as Predictors of Antidepressant Treatment Response in Major Depression. Psychopharmacology Bulletin. https://doi.org/10.64719/pb.4509

Vancouver

Kranzler HR, Stone A, Schichman SA, Griffin LM, Roggenkamp H, Thase ME, et al. Macrophage Migration Inhibitory Factor and Interleukin 1-β mRNA Levels as Predictors of Antidepressant Treatment Response in Major Depression. Psychopharmacology Bulletin. 2025. doi:10.64719/pb.4509

BibTeX
@article{Kranzler2025,
  author = {Kranzler, Henry R and Stone, Annjanette and Schichman, Steven A and Griffin, L Michelle and Roggenkamp, Hannah and Thase, Michael E and Lynch, Kevin G and Oslin, David W},
  title = {Macrophage Migration Inhibitory Factor and Interleukin 1-β mRNA Levels as Predictors of Antidepressant Treatment Response in Major Depression},
  journal = {Psychopharmacology Bulletin},
  year = {2025},
  doi = {10.64719/pb.4509}
}
Kostenlos starten →